Scotiabank analyst Greg Harrison raised the firm’s price target on Liquidia (LQDA) to $36 from $34 and keeps an Outperform rating on the shares. The firm is increasing its price target on the stock following the dismissal of United Therapeutic’s lawsuit against the FDA, alleging Yutrepia’s New Drug Application amendment violated the FDA’s policy, the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Court dismisses United Therapeutics’ dispute against Liquidia
- Positive Outlook for Liquidia Technologies: Buy Rating Affirmed Following Legal Victory and Anticipated FDA Approval
- Liquidia rallies after judge rules against bid to delay Yutrepia
- Liquidia price target raised at Scotiabank after ‘best case’ court ruling
- Legal Victory and Favorable Market Outlook Boost Liquidia Technologies to Buy Rating